MY186929A - Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production - Google Patents

Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Info

Publication number: MY186929A
Authority: MY; Malaysia
Prior art keywords: methods; production; dimeric immunoglobulins; hetero; cell retargeting
Prior art date: 2014-11-04

Application number

MYPI2017701499A

Other languages

English (en)

Inventor

Ollier Romain

Hou Samuel

Lissilaa Rami

Skegro Darko

Back Jonathan

Original Assignee

Ichnos Sciences SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-04

Filing date

2015-11-03

Publication date

2021-08-26

2014-11-04 Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/fr

2015-11-03 Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA

2021-08-26 Publication of MY186929A publication Critical patent/MY186929A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Obesity (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MYPI2017701499A 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production MY186929A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/EP2014/073738 WO2015063339A1 (fr)	2013-11-04	2014-11-04	Production de cellules t reciblant des immunoglobulines héréro-dimériques
EP15167034		2015-05-08
PCT/EP2015/075628 WO2016071355A1 (fr)	2014-11-04	2015-11-03	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Publications (1)

Publication Number	Publication Date
MY186929A true MY186929A (en)	2021-08-26

Family

ID=53059011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI2017701499A MY186929A (en)	2014-11-04	2015-11-03	Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Country Status (20)

Country	Link
EP (1)	EP3215541A1 (fr)
JP (3)	JP2018501297A (fr)
KR (1)	KR102760422B1 (fr)
CN (1)	CN107207596A (fr)
AU (1)	AU2015341884B2 (fr)
BR (1)	BR112017009263A2 (fr)
CA (1)	CA2965745C (fr)
CL (1)	CL2017001090A1 (fr)
CO (1)	CO2017005240A2 (fr)
EA (1)	EA039658B1 (fr)
HK (1)	HK1244014A1 (fr)
IL (1)	IL251848A0 (fr)
MA (1)	MA40894A (fr)
MX (1)	MX2017005814A (fr)
MY (1)	MY186929A (fr)
NZ (1)	NZ732019A (fr)
PE (1)	PE20171041A1 (fr)
PH (1)	PH12017500819A1 (fr)
SG (1)	SG11201703313SA (fr)
WO (1)	WO2016071355A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR102391731B1 (ko)	2013-01-14	2022-04-27	젠코어 인코포레이티드	신규한 이형이량체 단백질
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
JP6693872B2 (ja)	2013-07-25	2020-05-13	シトムクスセラピューティクス，インコーポレイティド	多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
AP2016009222A0 (en)	2013-11-04	2016-05-31	Glenmark Pharmaceuticals Sa	Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl)	2014-03-28	2020-06-15	Xencor, Inc.	Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
CA2955947A1 (fr)	2014-07-25	2016-01-28	Cytomx Therapeutics, Inc.	Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
HK1245171A1 (zh)	2014-11-26	2018-08-24	Xencor, Inc.	结合cd3和cd38的异二聚体抗体
JP6696982B2 (ja)	2014-11-26	2020-05-20	ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、Ｉｎｃ．	Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
EP3387013B1 (fr)	2015-12-07	2022-06-08	Xencor, Inc.	Anticorps hétérodimères se liant à cd3 et psma
AR107582A1 (es)	2016-02-03	2018-05-16	Amgen Res Munich Gmbh	Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
CA3026151A1 (fr)	2016-06-14	2017-12-21	Xencor, Inc.	Anticorps inhibiteurs de points de controle bispecifiques
RU2019102008A (ru)	2016-06-28	2020-07-28	Ксенкор, Инк.	Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
EP3615571A1 (fr) *	2017-04-24	2020-03-04	Ichnos Sciences SA	Anticorps bispécifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr
US11319371B2 (en)	2017-06-05	2022-05-03	Numab Therapeutics AG	Anti-CD3 antibodies
WO2018224441A1 (fr) *	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-cd3
KR102770106B1 (ko) *	2017-06-08	2025-02-21	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
US11780930B2 (en)	2017-06-08	2023-10-10	Black Belt Therapeutics Limited	CD38 modulating antibody
BR112020002636A2 (pt)	2017-08-10	2020-07-28	Grifols Diagnostic Solutions Inc.	composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
JP7299873B2 (ja)	2017-08-16	2023-06-28	ブラックベルトセラピューティクスリミテッド	Ｃｄ３８抗体
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
WO2019035938A1 (fr)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Molécules multispécifiques se liant à bcma et leurs utilisations
AU2018316521B2 (en)	2017-08-16	2025-01-30	Black Belt Therapeutics Limited	CD38 modulating antibody
CN111247171A (zh)	2017-10-14	2020-06-05	西托姆克斯治疗公司	抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
AU2018366199A1 (en)	2017-11-08	2020-05-28	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN112469477A (zh)	2018-04-04	2021-03-09	Xencor股份有限公司	与成纤维细胞活化蛋白结合的异源二聚体抗体
CA3113756A1 (fr) *	2018-09-25	2020-04-02	Ichnos Sciences S.A.	Quantification d'anticorps dans des echantillons biologiques
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN113614107A (zh)	2019-01-23	2021-11-05	Encefa公司	Cd31竞争剂及其用途
WO2020182984A2 (fr) *	2019-03-13	2020-09-17	Ichnos Sciences SA	Glycosylation sans consensus d'anticorps bispécifiques
KR20220012313A (ko) *	2019-05-23	2022-02-03	벨로스바이오 인코포레이티드	항-ror1/항-cd3 이중특이적 결합 분자
WO2020250940A1 (fr) *	2019-06-11	2020-12-17	小野薬品工業株式会社	Agent d'immunosuppression
CN110551222B (zh) *	2019-08-27	2023-06-06	重庆市畜牧科学院	一种新型双功能抗体及其用途
CN112538114B (zh) *	2019-09-20	2025-05-02	上海普铭生物科技有限公司	抗人cd38抗体及其应用
TWI841790B (zh) *	2019-09-30	2024-05-11	大陸商和鉑醫藥（上海）有限責任公司	靶向cd3的抗體、雙特異性抗體及其用途
CR20220330A (es) *	2019-12-13	2022-08-04	Genentech Inc	Anticuerpos anti-ly6g6d y métodos de uso.
CN113493519B (zh) *	2020-03-19	2022-12-27	浙江道尔生物科技有限公司	一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021185004A1 (fr)	2020-03-19	2021-09-23	深圳纽迪瑞科技开发有限公司	Appareil de détection de pression et dispositif de détection de pression
CN115803340A (zh) *	2020-04-24	2023-03-14	纪念斯隆凯特琳癌症中心	抗cd3抗体及其用途
EP4149632A1 (fr)	2020-05-14	2023-03-22	Xencor, Inc.	Anticorps hétérodimères se liant à msln et cd3
WO2021231976A1 (fr)	2020-05-14	2021-11-18	Xencor, Inc.	Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
CA3180690A1 (fr) *	2020-06-17	2021-12-23	Ahmed Mahiuddin	Anticorps anti-cd38 pour le traitement de maladies humaines
US11919958B2 (en)	2020-08-19	2024-03-05	Xencor, Inc.	Anti-CD28 compositions
EP4305067A1 (fr)	2021-03-09	2024-01-17	Xencor, Inc.	Anticorps hétérodimériques se liant à cd3 et à cldn6
US11859012B2 (en)	2021-03-10	2024-01-02	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and GPC3
KR20240040097A (ko) *	2021-08-04	2024-03-27	에이비프로 코퍼레이션	Cd3 표적화 항체 및 이의 용도
CN116724057A (zh) *	2022-11-28	2023-09-08	浙江时迈药业有限公司	蛋白酶可切割的重组双特异性抗体和组合物及其用途
CN118108852B (zh) *	2023-11-23	2025-11-18	浙江大学	一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒
CN120623348B (zh) *	2025-06-16	2026-06-09	江苏阿塔斯生物科技有限公司	一种抗人cd3兔重组单克隆抗体及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2915820A1 (fr) *	2004-02-06	2015-09-09	MorphoSys AG	Anticorps humains anti-CD38 et utilisations de ceux-ci
EP2551282A3 (fr) *	2005-03-23	2013-02-13	Genmab A/S	Anticorps diriges contre CD38 pour le traitement du myelome multiple
CN101287764B (zh) *	2005-10-12	2013-11-13	莫佛塞斯公司	特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
TWI507525B (zh) *	2009-06-26	2015-11-11	Regeneron Pharma	具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2010336277B2 (en) *	2009-12-25	2015-02-19	Chugai Seiyaku Kabushiki Kaisha	Polypeptide modification method for purifying polypeptide multimers
EP2580243B1 (fr) *	2010-06-09	2019-10-16	Genmab A/S	Anticorps dirigés contre le cd38 humain
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
JP2014511836A (ja) *	2011-03-25	2014-05-19	グレンマークファーマシューティカルズ，エセ．アー．	ヘテロ二量体免疫グロブリン
US20150239991A1 (en) *	2012-09-25	2015-08-27	Glenmark Pharmaceuticals S.A.	Purification of hetero-dimeric immunoglobulins
US9486547B2 (en) *	2012-11-05	2016-11-08	Morphosys Ag	Radiolabelled antibody and uses thereof
AP2016009222A0 (en) *	2013-11-04	2016-05-31	Glenmark Pharmaceuticals Sa	Production of t cell retargeting hetero-dimeric immunoglobulins

2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr not_active Ceased
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active

Also Published As

Publication number	Publication date
CO2017005240A2 (es)	2017-10-31
AU2015341884A1 (en)	2017-06-08
KR102760422B1 (ko)	2025-02-03
JP7403505B2 (ja)	2023-12-22
EA039658B1 (ru)	2022-02-22
CN107207596A (zh)	2017-09-26
JP2021184722A (ja)	2021-12-09
MA40894A (fr)	2017-09-12
KR20170078831A (ko)	2017-07-07
CL2017001090A1 (es)	2018-01-05
SG11201703313SA (en)	2017-05-30
EP3215541A1 (fr)	2017-09-13
HK1244014A1 (zh)	2018-07-27
EA201790961A1 (ru)	2017-10-31
MX2017005814A (es)	2017-08-02
JP2018501297A (ja)	2018-01-18
BR112017009263A2 (pt)	2018-01-30
CA2965745C (fr)	2023-12-05
IL251848A0 (en)	2017-06-29
PE20171041A1 (es)	2017-07-19
JP2019214582A (ja)	2019-12-19
CA2965745A1 (fr)	2016-05-12
PH12017500819A1 (en)	2017-10-02
WO2016071355A1 (fr)	2016-05-12
AU2015341884B2 (en)	2020-09-17
NZ732019A (en)	2022-07-29

Publication	Publication Date	Title
PH12017500819A1 (en)	2017-10-02	Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
SG10201902924RA (en)	2019-05-30	Antibodies that bind ebola glycoprotein and uses thereof
MX2018012757A (es)	2019-06-24	Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
EP4249515A3 (fr)	2023-11-15	Anticorps anti-cd3 humanisés ou chimériques
MX2021003704A (es)	2021-06-04	Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12016501366A1 (en)	2016-08-15	Novel anti-baff antibodies
MX2018008934A (es)	2019-03-28	Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890305A1 (ru)	2018-07-31	Гуманизированные или химерные cd3-антитела
MX2022002364A (es)	2022-04-06	Anticuerpos anti-pd-l1.
TN2017000470A1 (en)	2019-04-12	Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2016016883A (es)	2018-03-02	Anticuerpo anti-axl.
PH12016501908A1 (en)	2017-01-09	Bispecific antibodies that bind to cd38 and cd3
EA201890285A1 (ru)	2018-08-31	Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2016009050A (es)	2016-12-09	Construcciones biespecificas de union a los antigenos cd3 y cd19.
EA201791485A1 (ru)	2018-02-28	Анти-cd47-антитела и их применения
SA520420582B1 (ar)	2024-02-15	Cd3 أجسام مضادة خاصة لـ واستخداماتها
PH12016501212B1 (en)	2021-06-23	Human anti-il-33 neutralizing monoclonal antibody
GEP20227343B (en)	2022-01-25	Anti-lag3 antibodies and antigen-binding fragments
PH12017501077A1 (en)	2017-11-06	Compositions and methods for antibodies targeting bmp6
NZ730186A (en)	2020-04-24	Humanized anti-hepcidin antibodies and uses thereof
ZA201800804B (en)	2023-12-20	Novel anti-human gpvi antibodies and uses thereof
MX376061B (es)	2025-03-07	Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).
MA40526A (fr)	2017-06-28	Protéines de fixation antigénique fixant le cxcr3
MX2017003014A (es)	2017-05-30	Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2016014726A (es)	2017-03-23	Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.